Nothing Special   »   [go: up one dir, main page]

ID27576A - Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun - Google Patents

Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun

Info

Publication number
ID27576A
ID27576A IDW20002433A ID20002433A ID27576A ID 27576 A ID27576 A ID 27576A ID W20002433 A IDW20002433 A ID W20002433A ID 20002433 A ID20002433 A ID 20002433A ID 27576 A ID27576 A ID 27576A
Authority
ID
Indonesia
Prior art keywords
cycosporine
autoimun
treatment
disease diseases
diseases
Prior art date
Application number
IDW20002433A
Other languages
English (en)
Inventor
Peter Hiestand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ID27576A publication Critical patent/ID27576A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IDW20002433A 1998-06-02 1999-05-31 Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun ID27576A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds

Publications (1)

Publication Number Publication Date
ID27576A true ID27576A (id) 2001-04-12

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002433A ID27576A (id) 1998-06-02 1999-05-31 Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun

Country Status (17)

Country Link
EP (1) EP1082130A1 (id)
JP (2) JP4523154B2 (id)
KR (1) KR20010043969A (id)
CN (1) CN1304315A (id)
AU (1) AU750422B2 (id)
BR (1) BR9910860A (id)
CA (1) CA2333315A1 (id)
GB (1) GB9811854D0 (id)
HU (1) HUP0102142A3 (id)
ID (1) ID27576A (id)
IL (1) IL139589A0 (id)
NO (1) NO20006113L (id)
PL (1) PL344451A1 (id)
SK (1) SK18142000A3 (id)
TW (2) TWI250022B (id)
WO (1) WO1999062540A1 (id)
ZA (1) ZA200006464B (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243314T3 (es) 1999-10-27 2005-12-01 Alexandra Lucas Composiciones para la prevencion y el tratamiento del rechazo de trasplantes.
EP1365798B1 (en) * 2000-09-29 2009-12-30 Viron Therapeutics, Inc. Use of serp-1 in combination with an immunosuppressant for treating arthritis
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
AU2005230400A1 (en) * 2004-04-08 2005-10-20 Novartis Ag Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury
WO2006005610A1 (en) 2004-07-14 2006-01-19 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv)
AU2005290984B2 (en) * 2004-10-01 2010-09-09 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
AU2005322242B2 (en) * 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment
CA2587586A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compounds for flaviviridae treatment
AU2006259348B2 (en) * 2005-06-17 2010-07-22 Novartis Ag Use of sanglifehrin in HCV
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
JP2013513595A (ja) * 2009-12-09 2013-04-22 サイネクシス，インコーポレーテッド 新規環状ペプチド
CN104603146B (zh) 2012-09-29 2018-01-02 诺华股份有限公司 环肽类化合物及其作为药物的用途
WO2014063147A1 (en) * 2012-10-19 2014-04-24 Scynexis, Inc. New antiviral macrocycles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148469T1 (de) * 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) * 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky

Also Published As

Publication number Publication date
CN1304315A (zh) 2001-07-18
JP2002516873A (ja) 2002-06-11
JP4523154B2 (ja) 2010-08-11
PL344451A1 (en) 2001-11-05
EP1082130A1 (en) 2001-03-14
WO1999062540A1 (en) 1999-12-09
HUP0102142A3 (en) 2001-12-28
NO20006113D0 (no) 2000-12-01
KR20010043969A (ko) 2001-05-25
GB9811854D0 (en) 1998-07-29
ZA200006464B (en) 2002-03-11
HUP0102142A2 (hu) 2001-11-28
NO20006113L (no) 2001-01-25
JP2010059177A (ja) 2010-03-18
TWI250021B (en) 2006-03-01
IL139589A0 (en) 2002-02-10
AU4372499A (en) 1999-12-20
SK18142000A3 (sk) 2001-06-11
CA2333315A1 (en) 1999-12-09
BR9910860A (pt) 2001-03-06
AU750422B2 (en) 2002-07-18
TWI250022B (en) 2006-03-01
TW200522975A (en) 2005-07-16

Similar Documents

Publication Publication Date Title
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
FIU20060389U0 (fi) Luusairauksien hoito
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
NO994014D0 (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
PT1028954E (pt) Imidazoles substituidos uteis no tratamento de doencas inflamatorias
DK1031346T3 (da) Ikke-invasiv vaccination gennem huden
EE04156B1 (et) Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
EE200300214A (et) Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
ID28111A (id) Metoda untuk meningkatkan kesehatan kulit
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20005179D0 (no) Medikament behandling
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
ITMI20001216A0 (it) Impiego dell'aloe-emodin nel trattamento di patologie neoplastiche diorigine neuroectodermica
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
NO20010044L (no) Anvendelse av texafyriner i makrofag-medierte sykdommer
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
EP1322778A4 (en) APPLICATION OF CYR61 IN THE TREATMENT AND DIAGNOSIS OF HUMAN UTERUS MYOMENIC
EP1107778A4 (en) TREATMENT OF DISEASE CONDITIONS
GB9908059D0 (en) Diagnosis and treatment of diseases